These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12700662)

  • 1. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
    Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
    Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
    Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
    J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus from Burkitt Lymphoma biopsies from Africa and South America share novel LMP-1 promoter and gene variations.
    Lei H; Li T; Li B; Tsai S; Biggar RJ; Nkrumah F; Neequaye J; Gutierrez M; Epelman S; Mbulaiteye SM; Bhatia K; Lo SC
    Sci Rep; 2015 Nov; 5():16706. PubMed ID: 26593963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the global burden of Epstein-Barr virus-related cancers.
    Wong Y; Meehan MT; Burrows SR; Doolan DL; Miles JJ
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):31-46. PubMed ID: 34705104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
    Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
    Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
    Lechner M; Schartinger VH; Steele CD; Nei WL; Ooft ML; Schreiber LM; Pipinikas CP; Chung GT; Chan YY; Wu F; To KF; Tsang CM; Pearce W; Morelli D; Philpott M; Masterson L; Nibhani R; Wells G; Bell CG; Koller J; Delecluse S; Yip YL; Liu J; Forde CT; Forster MD; Jay A; Dudás J; Krapp A; Wan S; Uprimny C; Sprung S; Haybaeck J; Fenton TR; Chester K; Thirlwell C; Royle G; Marafioti T; Gupta R; Indrasari SR; Herdini C; Slim MAM; Indrawati I; Sutton L; Fles R; Tan B; Yeong J; Jain A; Han S; Wang H; Loke KSH; He W; Xu R; Jin H; Cheng Z; Howard D; Hwang PH; Le QT; Tay JK; West RB; Tsao SW; Meyer T; Riechelmann H; Oppermann U; Delecluse HJ; Willems SM; Chua MLK; Busson P; Lo KW; Wollmann G; Pillay N; Vanhaesebroeck B; Lund VJ
    Nat Commun; 2021 Jan; 12(1):117. PubMed ID: 33402692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted eradication of EBV-positive cancer cells by CRISPR/dCas9-mediated EBV reactivation in combination with ganciclovir.
    Sugiokto FG; Li R
    mBio; 2024 Jul; 15(7):e0079524. PubMed ID: 38874417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.
    Ma Y; Walsh MJ; Bernhardt K; Ashbaugh CW; Trudeau SJ; Ashbaugh IY; Jiang S; Jiang C; Zhao B; Root DE; Doench JG; Gewurz BE
    Cell Host Microbe; 2017 May; 21(5):580-591.e7. PubMed ID: 28494239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma.
    Xie J; Wang Z; Fan W; Liu Y; Liu F; Wan X; Liu M; Wang X; Zeng D; Wang Y; He B; Yan M; Zhang Z; Zhang M; Hou Z; Wang C; Kang Z; Fang W; Zhang L; Lam EW; Guo X; Yan J; Zeng Y; Chen M; Liu Q
    Signal Transduct Target Ther; 2021 Sep; 6(1):333. PubMed ID: 34482361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in cellular expression in EBV infected epithelial cell lines and tumors.
    Edwards RH; Dekroon R; Raab-Traub N
    PLoS Pathog; 2019 Oct; 15(10):e1008071. PubMed ID: 31584998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.
    Bakkalci D; Jia Y; Winter JR; Lewis JE; Taylor GS; Stagg HR
    J Glob Health; 2020 Jun; 10(1):010405. PubMed ID: 32257153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of Epstein-Barr Virus in breast cancer development.
    Gouadfel K; Khenchouche A; Rabea S; Mansour AA; Salem-Bekhit MM; Ouhida S; Msela A; Salem MM; Erto A; Benguerba Y; Houali K
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(13):241-249. PubMed ID: 38158663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OTUD1 enhances gastric cancer aggressiveness by deubiquitinating EBV-encoded protein BALF1 to stabilize the apoptosis inhibitor Bcl-2.
    Lin H; Han Y; Sang Y; Wu Y; Tian M; Chen X; Lin X; Lin X
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167132. PubMed ID: 38565386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy-mediated modulation of inflammatory cytokine production by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.
    Koon HK; Lo KW; Leung KN; Lung ML; Chang CC; Wong RN; Leung WN; Mak NK
    Cell Mol Immunol; 2010 Jul; 7(4):323-6. PubMed ID: 20228836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.
    Bentz GL; Lowrey AJ; Horne DC; Nguyen V; Satterfield AR; Ross TD; Harrod AE; Uchakina ON; McKallip RJ
    PLoS One; 2019; 14(5):e0217578. PubMed ID: 31125383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.
    Grande BM; Gerhard DS; Jiang A; Griner NB; Abramson JS; Alexander TB; Allen H; Ayers LW; Bethony JM; Bhatia K; Bowen J; Casper C; Choi JK; Culibrk L; Davidsen TM; Dyer MA; Gastier-Foster JM; Gesuwan P; Greiner TC; Gross TG; Hanf B; Harris NL; He Y; Irvin JD; Jaffe ES; Jones SJM; Kerchan P; Knoetze N; Leal FE; Lichtenberg TM; Ma Y; Martin JP; Martin MR; Mbulaiteye SM; Mullighan CG; Mungall AJ; Namirembe C; Novik K; Noy A; Ogwang MD; Omoding A; Orem J; Reynolds SJ; Rushton CK; Sandlund JT; Schmitz R; Taylor C; Wilson WH; Wright GW; Zhao EY; Marra MA; Morin RD; Staudt LM
    Blood; 2019 Mar; 133(12):1313-1324. PubMed ID: 30617194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflatoxin B1 and Epstein-Barr virus-induced CCL22 expression stimulates B cell infection.
    Maroui MA; Odongo GA; Mundo L; Manara F; Mure F; Fusil F; Jay A; Gheit T; Michailidis TM; Ferrara D; Leoncini L; Murray P; Manet E; Ohlmann T; De Boevre M; De Saeger S; Cosset FL; Lazzi S; Accardi R; Herceg Z; Gruffat H; Khoueiry R
    Proc Natl Acad Sci U S A; 2024 Apr; 121(16):e2314426121. PubMed ID: 38574017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus and Burkitt lymphoma.
    Rowe M; Fitzsimmons L; Bell AI
    Chin J Cancer; 2014 Dec; 33(12):609-19. PubMed ID: 25418195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr Virus: Human Interactome Reveals New Molecular Insights into Viral Pathogenesis for Potential Therapeutics and Antiviral Drug Discovery.
    Krishnan D; Babu S; Raju R; Veettil MV; Prasad TSK; Abhinand CS
    OMICS; 2024 Jan; 28(1):32-44. PubMed ID: 38190109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond.
    Eladwy RA; Vu HT; Shah R; Li CG; Chang D; Bhuyan DJ
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.